MARK LESCHLY
CIK 1120545 · last filed 2026-07-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$601.2K
Companies
12
Total Filings
39
Lifetime Open-Market Net
$41.67M
Filer Profile
Reported Address
RHO CAPITAL PARTNERS, INC.152 W 57TH ST 23RD FL
NEW YORK, NY 10019
State of Incorporation
NY
Related Filers
JOSHUA RUCH — 38 joint filings, latest 2021-02-08
Rho Capital Partners LLC — 24 joint filings, latest 2021-02-08
HABIB KAIROUZ — 23 joint filings, latest 2021-02-08
RHO VENTURES IV GMBH & CO BETEILIGUNGS KG — 14 joint filings, latest 2017-01-19
RHO VENTURES IV QP LP — 14 joint filings, latest 2017-01-19
Rho Ventures III Holdings LLC — 6 joint filings, latest 2021-02-08
Rho Ventures Partners Holdings LLC — 3 joint filings, latest 2016-12-06
Rho Ventures IV-A, L.P. — 2 joint filings, latest 2015-02-25
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CHPT | Director | 60,792 | $9.89 | $601.2K | $0 | 6 | 2026-07-22 |
| ChargePoint Holdings, Inc. (CHPT.WS) Delisted | Director | 439,446 | $20.53 | $9.02M | $0 | 4 | 2021-07-02 |
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Director | 3,766,667 | $1.54 | $5.80M | $0 | 4 | 2021-06-10 |
| Tvardi Therapeutics, Inc. (CARA) Delisted | 10%+ Owner | 99,113 | $15.96 | $1.58M | $81.17M | 3 | 2017-04-03 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Director | 2,787,674 | $10.19 | $28.41M | $11.71M | 8 | 2016-06-24 |
| IntraLinks Holdings, Inc. (IL) Delisted | 10%+ Owner | 3,858,495 | — | — | -$12.50M | 2 | 2015-09-16 |
| NephroGenex, Inc. (NRX) Delisted | 10%+ Owner | 1,073,907 | — | — | -$20.29M | 1 | 2015-01-06 |
| ReachLocal Inc (RLOC) Delisted | 10%+ Owner | 2,756,966 | — | — | -$18.42M | 1 | 2012-11-30 |
| VERENIUM CORP (VRNM) Delisted | Director | 216,264 | — | — | $0 | 3 | 2009-02-18 |
| TERCICA INC (TRCA) Delisted | Director | 885,304 | $7.87 | $6.97M | $0 | 2 | 2008-05-22 |
| NITROMED INC (NTMD) Delisted | Director | — | — | — | $0 | 2 | 2008-05-16 |
| SENOMYX INC (SNMX) Delisted | Director | — | — | — | $0 | 1 | 2007-06-04 |
Recent Filings · Page 3 of 4
39 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-01-06 | NephroGenex, Inc. (NRX) Delisted | Sell (S) | −1,917,020 | -$20.29M | EDGAR |
| 2014-08-29 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Sell (S) | −13,067 | -$294.0K | EDGAR |
| 2014-02-05 | Tvardi Therapeutics, Inc. (CARA) Delisted | Mixed | +16,008,342 | $14.90M | EDGAR |
| 2013-06-07 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-11-30 | ReachLocal Inc (RLOC) Delisted | Sell (S) | −1,650,000 | -$18.42M | EDGAR |
| 2012-06-01 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-05-26 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-04-04 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-12-01 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Mixed | +5,621,423 | $12.00M | EDGAR |
| 2009-04-28 | — | Disp (D) | −4,872,002 | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.